Edition:
United States

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

3.69USD
20 Oct 2017
Change (% chg)

$-0.01 (-0.27%)
Prev Close
$3.70
Open
$3.70
Day's High
$3.72
Day's Low
$3.60
Volume
18,474
Avg. Vol
49,979
52-wk High
$5.43
52-wk Low
$2.89

Latest Key Developments (Source: Significant Developments)

Zafgen appoints Jeffrey Hatfield as CEO
Tuesday, 10 Oct 2017 07:00am EDT 

Oct 10 (Reuters) - Zafgen Inc ::Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer.Zafgen Inc - Hatfield and Hughes will serve on Zafgen's board of directors​.  Full Article

Zafgen initiates Phase 2 clinical trial for ZGN-1061
Tuesday, 12 Sep 2017 04:05pm EDT 

Sept 12 (Reuters) - Zafgen Inc :Zafgen initiates Phase 2 clinical trial for ZGN-1061 in patients with Type 2 diabetes.  Full Article

Zafgen Inc files for a potential mixed shelf offering of up to $150 mln
Wednesday, 9 Aug 2017 04:49pm EDT 

Aug 9 (Reuters) - Zafgen Inc :Zafgen Inc files for a potential mixed shelf offering of up to $150 million - SEC filing.  Full Article

Zafgen Q2 loss per share $0.49
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Zafgen Inc :Zafgen reports second quarter 2017 financial results.Q2 loss per share $0.49.Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

Zafgen reports Q1 loss per share $0.48
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Zafgen Inc :Zafgen reports first quarter 2017 financial results.Q1 loss per share $0.48.Q1 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.Zafgen Inc says expects that its cash, cash equivalents and marketable securities balance will be greater than $65 million as of December 31, 2017.  Full Article

Zafgen reports Q4 loss per share of $0.38
Thursday, 9 Mar 2017 04:05pm EST 

Zafgen Inc : Zafgen reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.38 . Q4 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S .Expects Co's cash, cash equivalents and marketable securities balance will be greater than $65 million as of December 31, 2017.  Full Article

Zafgen posts Q2 shr loss $0.55
Thursday, 4 Aug 2016 04:05pm EDT 

Zafgen Inc : Q2 loss per share $0.55 . Zafgen reports second quarter 2016 financial results . Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S .Says expects that its cash, cash equivalents and marketable securities balance will be greater than $125 million at december 31, 2016.  Full Article

Zafgen Q1 loss per share $0.65
Tuesday, 10 May 2016 04:05pm EDT 

Zafgen Inc : Reported a net loss for q1 of $0.65 per share . Expects that its cash, cash equivalents and marketable securities balance will be greater than $100 million at December 31, 2016 . Zafgen inc says expect to have more clarity on potential path forward for beloranib in PWS over next few months . Zafgen reports first quarter 2016 financial results . Q1 loss per share $0.65 .Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Zafgen Inc and Lead Plaintiff Deadline - ACSWIR
Thursday, 17 Dec 2015 10:01am EST 

Zafgen Inc:Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the District of Massachuesetts on behalf of those who purchased shares of Zafgen, Inc during the period between Jan.12, 2015 and Oct.16, 2015 - ACSWIR.The complaint alleges that Zafgen made false and/or misleading statements and/or failed to disclose to investors that - ACSWIR.one participant in the beloranib Phase 3 study, who had died, was receiving beloranib and not a placebo - ACSWIR.while Zafgen had reported 2 thrombotic events in prior clinical studies, there had actually been 4 such events, as well as 2 additional thrombotic events in other ongoing studies - ACSWIR.and consequently, Defendants' statements about Zafgen's business, operations and prospects were false and misleading and/or lacked a reasonable basis - ACSWIR.  Full Article

Zafgen Inc halts obesity drug trial after second patient death - Reuters
Wednesday, 2 Dec 2015 08:12pm EST 

Zafgen Inc:Zafgen Inc said the U.S. Food and Drug Administration was putting a late-stage study testing its experimental obesity drug on complete hold after a second patient died during the trial - RTRS.The company's shares fell 7.4 percent to $5.81 in extended trading after closing down 60 percent on Wednesday - RTRS.A complete clinical hold is an order that the FDA issues to a sponsor to suspend all clinical work requested under the company's investigational new drug application - RTRS.Earlier on Wednesday, the company had said a patient receiving the obesity drug, beloranib, had died from a blockage in an artery in the lungZafgen - RTRS.which is testing beloranib for a rare genetic eating disorder called Prader-Willi syndrome, expects to report results from the study in the first quarter - RTRS.The company said it was working with experts to better understand the incidence and the occurrence of such artery blockages in Prader-Willi syndrome patients - RTRS.The company said in October a patient had died in the trial, but the cause of death was unknown. Following the disclosure the FDA placed the trial under a partial clinical hold, citing previously reported blood clotting in ongoing and completed studies - RTRS.The two deaths in the 108-patient study come after clean smaller studies on the drug, where the most severe side-effect seen was bruising where the patients were given the injection - RTRS.  Full Article

BRIEF-Zafgen appoints Jeffrey Hatfield as CEO

* Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer